BioTech Pharma Summit: Companion Diagnostics & Biomarkers

Predictive Biomarkers and Companion Diagnostics to Guide Cancer Immunotherapy

Anand Subramony

June 16, 2017

Anand Subramony is Vice President of Novel Product Technologies at MedImmune, the global biological arm of AstraZeneca. In this role, Dr. Subramony heads the function from the CTO office and oversees efforts on digital health and precision medicine. Key focus areas are creating patient centric products that rely on the principles of digital health, connected devices/drug-device combination products and other novel technologies for the diverse portfolio including diagnostics and sensors. Dr. Subramony also focusses in evaluating disruptive delivery technologies in the areas of drug targeting/nanomedicine, and novel biologics. Dr. Subramony in his career has successfully built teams and led projects to product launches. Before his current role, Dr. Subramony was Principal Fellow and Director of the Novel Delivery Technologies & Therapeutics program at the Novartis Institute for BioMedical Research (Cambridge, MA) where he established and managed a high performing cross functional team that led several evaluations with a culture of execution excellence and quick decision making.

In his other roles, Dr. Subramony led the Materials Research group at ALZA Corporation/J&J where he focused on drug delivery technologies across various transmucosal interface and was also the Director of Center of Excellence for Materials Science & Drug delivery devices at Dr. Reddy’s Laboratories, Research Scientist at University of Washington Seattle, and also served as Global Technical Program Manager at Applied Materials. Dr. Subramony is known for his exemplary leadership style, cross functional approach and execution excellence and effectively combines scientific excellence with business acumen. A proponent of “connected health devices” Dr. Subramony’s vision is to monitor and track combination product and device usage via smart phones for improved compliance and adherence and correlate with patient outcomes

Dr. Subramony holds an MS in Materials Sc. & Engineering from IIT Bombay and PhD from Purdue University and also serves in the scientific advisory board for various organizations and has several refereed publications and patents.